Journal Article

Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients

Scambia, Giovanni, Ciucci, Alessandra, Fagotti, Anna, Palluzzi, Fernando, Perrone, Emanuele, Buttarelli, Marianna, Minucci, Angelo, Giacò, Luciano, Gallo, Daniela, Raspaglio, Giuseppina, Marchetti, Claudia

2022

Overview

Background High-grade serous ovarian cancer (HGSOC) has poor survival rates due to a combination of diagnosis at advanced stage and disease recurrence as a result of chemotherapy resistance. In BRCA1 (Breast Cancer gene 1) - or BRCA2-wild type (BRCAwt) HGSOC patients, resistance and progressive disease occur earlier and more often than in mutated BRCA. Identification of biomarkers helpful in predicting response to first-line chemotherapy is a challenge to improve BRCAwt HGSOC management. Methods To identify a gene signature that can predict response to first-line chemotherapy, pre-treatment tumor biopsies from a restricted cohort of BRCAwt HGSOC patients were profiled by RNA sequencing (RNA-Seq) technology. Patients were sub-grouped according to platinum-free interval (PFI), into sensitive (PFI > 12 months) and resistant (PFI < 6 months). The gene panel identified by RNA-seq analysis was then tested by high-throughput quantitative real-time PCR (HT RT-qPCR) in a validation cohort, and statistical/bioinformatic methods were used to identify eligible markers and to explore the relevant pathway/gene network enrichments of the identified gene set. Finally, a panel of primary HGSOC cell lines was exploited to uncover cell-autonomous mechanisms of resistance. Results RNA-seq identified a 42-gene panel discriminating sensitive and resistant BRCAwt HGSOC patients and pathway analysis pointed to the immune system as a possible driver of chemotherapy response. From the extended cohort analysis of the 42 DEGs (differentially expressed genes), a statistical approach combined with the random forest classifier model generated a ten-gene signature predictive of response to first-line chemotherapy. The ten-gene signature included: CKB (Creatine kinase B), CTNNBL1 (Catenin, beta like 1), GNG11 (G protein subunit gamma 11), IGFBP7 (Insulin-like growth factor-binding protein 7), PLCG2 (Phospholipase C, gamma 2), RNF24 (Ring finger protein 24), SLC15A3 (Solute carrier family 15 member 3), TSPAN31 (Tetraspanin 31), TTI1 (TELO2 interacting protein 1) and UQCC1 (Ubiquinol-cytochrome c reductase complex assembly factor). Cytotoxicity assays, combined with gene-expression analysis in primary HGSOC cell lines, allowed to define CTNNBL1, RNF24, and TTI1 as cell-autonomous contributors to tumor resistance. Conclusions Using machine-learning techniques we have identified a gene signature that could predict response to first-line chemotherapy in BRCAwt HGSOC patients, providing a useful tool towards personalized treatment modalities.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Analysis / Apoptosis / Ascites / Bioinformatics / Biomarkers / Biomedical and Life Sciences / Biomedicine / BRCA1 Protein - genetics / Breast cancer / Cancer / Cancer Research / Cancer therapies / Cell culture / Chemotherapy / Cloning / Creatine / Creatine kinase / Cytokeratin / Diseases / Drug resistance / Drugging cancer vulnerabilities toward innovative clinical trials / Female / Fibroblasts / G proteins / Gene Expression Profiling - methods / Genes / Genetic aspects / Genetic research / HGSOC / Humans / Immunology / Machine learning / Medical prognosis / Neoplasm Grading / Oncology / Ovarian cancer / Ovarian Neoplasms - genetics / Ovarian Neoplasms - mortality / Ovarian Neoplasms - pathology / Patient stratification / Patients / Prognosis / Protein binding / Relapse / Retrospective Studies / RNA / RNA sequencing / Surgery / Survival Analysis / Transcriptomic / Tumors / Womens health